Baseline characteristics of the study patients by group
| Number (%) with the characteristic | |||
|---|---|---|---|
| Variable | Atorvastatin (n=99) | Placebo (n=101) | p Value |
| Age | |||
| 18–34 | 15 (15%) | 20 (20%) | 0.31 |
| 35–49 | 55 (56%) | 45 (45%) | |
| 50–64 | 23 (23%) | 32 (32%) | |
| 65–78 | 6 (6%) | 4 (4%) | |
| Race | |||
| Black | 35 (35%) | 31 (31%) | 0.77 |
| White | 59 (60%) | 64 (63%) | |
| Other | 5 (5%) | 6 (6%) | |
| Gender | |||
| Female | 89 (90%) | 95 (94%) | 0.29 |
| Male | 10 (10%) | 6 (6%) | |
| Years since SLE diagnosis | |||
| 0–2 | 12 (12%) | 11 (11%) | 0.13 |
| 2–5 | 15 (15%) | 25 (25%) | |
| 5–10 | 24 (24%) | 30 (30%) | |
| 10+ | 48 (48%) | 34 (34%) | |
| Hypertension | 49 (49%) | 48 (48%) | 0.78 |
| Diabetes mellitus | 4 (4%) | 5 (5%) | 0.76 |
| Total cholesterol (mg/dl) | |||
| ≤200 | 68 (69%) | 65 (64%) | 0.18 |
| 200–240 | 27 (27%) | 25 (25%) | |
| >240 | 4 (4%) | 11 (11%) | |
| LDL cholesterol (mg/dl) | |||
| ≤100 | 55 (56%) | 48 (48%) | 0.57 |
| 100–130 | 25 (25%) | 27 (27%) | |
| >130 | 19 (19%) | 24 (24%) | |
| HDL cholesterol (mg/dl) | |||
| <50 | 33 (33%) | 27 (27%) | 0.45 |
| 50–59 | 26 (26%) | 24 (24%) | |
| 60+ | 40 (40% | 49 (49%) | |
| Triglycerides (mg/dl) (1 missing) | |||
| <150 | 76 (77%) | 85 (85%) | 0.13 |
| 150–199 | 13 (13%) | 5 (5%) | |
| 200+ | 10 (10%) | 10 (10%) | |
| Coronary artery calcium score | |||
| 0 | 57 (58%) | 58 (57%) | 0.99 |
| >0–10 | 22 (22%) | 23 (23%) | |
| 11–99 | 12 (12%) | 11 (11%) | |
| 100–400 | 3 (3%) | 4 (4%) | |
| 401+ | 5 (5%) | 5 (5%) | |
| Intima media thickness (mm) | |||
| 0.4–0.5 | 21 (21%) | 26 (26%) | 0.35 |
| 0.5–0.6 | 42 (42%) | 50 (50%) | |
| 0.6–0.7 | 23 (23%) | 15 (15%) | |
| 0.7–1.1 | 13 (13%) | 10 (10%) | |
| Carotid plaque | |||
| No | 78 (80%) | 84 (85%) | 0.41 |
| Yes | 19 (20% | 15 (15%) | |
| Not done | 2 | 2 | |